Please login to the form below

Not currently logged in
Email:
Password:

Human vaccines to boom by 2013

The global market for human vaccines is expected to expand by more than 50 per cent over the next five years, with paediatric products and adult therapeutic vaccines driving rapid growth, according to a new US report.

The global market for human vaccines is expected to expand by more than 50 per cent over the next five years, with paediatric products and adult therapeutic vaccines driving rapid growth, according to a new US report.

Industry interest in the vaccines sector has been gaining momentum for several years on the back of new developments in technology, spurred on in some quarters by the perceived 'saturation point' with regard to potential to develop future primary care pharmaceutical blockbusters. According to a new report from BCC Research, large multinational corporations are positively stepping up proprietary vaccine development and marketing operations, building up a pipeline of products for tackling big killers, including cancer and HIV/AIDS.

The global market for human vaccines is expected to hit USD18.7bn in 2008, rising rapidly to USD31.3bn by 2013, equating to a compound average growth rate of 10.9 per cent per year over the next five years. BCC Research forecasts this aggressive escalation based on information that pricing concerns in developed nations are no longer deemed to affect the narrow margins expected on vaccine products so severely. New markets for vaccines are also opening up, the report suggests.

"While some time ago manufacturers were seen to be quitting this area due to a limited portfolio of products with narrowing margins, there has been a paradigm shift in the economics," the report states. "Public supply of undifferentiated routine and immunisation vaccines is now the primary domain of local regional players from countries such as China, India and Korea. This has led to a burgeoning of revenues and pipeline of adult and therapeutic vaccines such as those for various cancers, and combination vaccines."

New vaccine technologies

According to the report, patent offices in Europe and the US have received applications related to vaccine discovery numbering approximately 250 per year in 2006 and 2007. The number of clinical trials underway for prophylactic and therapeutic vaccines is also said to reflect this 'frenzied' interest.

Some of the most significant breakthroughs in vaccine technology pertain to the DNA-related products, offering notable progression over traditional vaccines with regard to immune response, stability and scalability of production.

The full report can be viewed at www.bccresearch.com.

24th January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics